Tatsuya Shiraki, Eiji Takayama, Hirohito Magari, Takahiro Nakata, Takao Maekita, Shotaro Enomoto, Yoshiyuki Mori, Naoki Shingaki, Kosaku Moribata, Hisanobu Deguchi, Kazuki Ueda, Izumi Inoue, Masako Mizuno-Kamiya, Koji Yashiro, Mikitaka Iguchi, Hideyuki Tamai, Yasunaga Kameyama, Jun Kato, Nobuo Kondoh, Masao Ichinose
ONCOLOGY REPORTS 26(1) 201-208 2011年7月 査読有り
Although CD57(+) lymphocytes are closely correlated with prognosis in various cancers, the role of subsets of CD57(+) cells in hepatitis C virus (HCV)-related hepatocellular carcinoma (HCC) is unclear. In the present study, peripheral blood (PB) from HCV-related HCC patients was analyzed. Plasma cytokine levels and in vitro cytokine-producing capabilities were analyzed with enzyme-linked immunosorbent assays, and CD57(+) cell subsets were studied using a multi-color FACS system. Interferon (IFN)-gamma was undetectable in the plasma of patients with tumors at any stage, whereas the plasma levels of tumor necrosis factor (TNF)-alpha, interleukin (IL)-10 and IL-18, but not that of IL-12, were significantly higher in stage IV patients compared to patients with earlier-stage tumors. In contrast, the IFN-gamma-producing capability of PB was highest in stage I patients and gradually decreased with tumor progression. The IL-10-, IL-18- and IL-12-proclucing capabilities of PB increased from stage I to III. However, PB-TNF-alpha, IL-10- and IL-18-producing capabilities were reduced in stage IV patients, probably due to repeated anti-cancer treatments. The percentage of CD4(+)CD57(+)alpha beta TCR+ cells (CD4(+)CD57(+) T cells) in peripheral blood lymphocytes (PBLs) increased with tumor progression. Moreover, the percentage of CD4(+)CD57(+) T cells in PBLs and the ratio of CD4(+)CD57(+) T cells to CD4(+)alpha beta TCR+ cells (CD4(+) T cells), but not that of CD4(+)CD57(+) T cells to CD57(+)alpha beta TCR+ cells (CD57(+) T cells), showed a significant inverse correlation with PB-IFN-gamma-producing capability. The present results suggest that an increase in CD4(+)CD57(+) T cells controls the capability of PB to produce the antitumor cytokine IFN-gamma and that PB-IFN-gamma production is impaired with HCC tumor progression.